Хлебные крошки
- Главная
-
Аналитика
-
Акции
Акции внутренные
Monte Rosa Therapeutics, Inc. GLUE
$5.80
-$0.05 (-0.85%)
На 18:04, 12 мая 2023
Ранг: 3
Ключевые показатели
-
Marketcap
309208136.00000000
-
week52high
12.62
-
week52low
4.40
-
Revenue
0
-
P/E TTM
-2
-
Beta
0.00000000
-
EPS
-2.49000000
-
Last Dividend
0.00000000
-
Next Earnings Date
10 мая 2023 г. в 04:00
Описание компании
Monte Rosa Therapeutics, Inc., a biopharmaceutical company, engages in the development of novel small molecule precision medicines that employ the body's natural mechanisms to selectively degrade therapeutically relevant proteins. It develops an oral molecular glue degrader for GSPT1, a translational termination factor and degron-containing protein for the treatment of Myc-driven cancers. The company also develops CDK2 to treat ovarian, uterine, and breast cancers; NEK7 for the treatment of inflammatory diseases, such as Crohn's disease, neurodegenerative disease, diabetes, and liver disease; VAV1, a target protein for autoimmune diseases; and BCL11A, a therapeutically-relevant protein in hemoglobinopathies. Monte Rosa Therapeutics, Inc. was incorporated in 2019 and is headquartered in Boston, Massachusetts.
Рекомендации
аналитиков
Рекомендации аналитиков
| Grading company | New grade | Previous grade | Recommendation date |
|---|---|---|---|
| Credit Suisse | Neutral | 22 авг 2022 г. | |
| Jefferies | Buy | 15 авг 2022 г. | |
| Piper Sandler | Overweight | Overweight | 12 мая 2022 г. |
| Credit Suisse | Neutral | 28 апр 2022 г. | |
| Wells Fargo | Equal-Weight | 10 февр 2022 г. | |
| UBS | Buy | 13 окт 2022 г. | |
| Wells Fargo | Overweight | Equal-Weight | 03 янв 2023 г. |
Свежие комментарии
Свежие комментарии
Оставьте свой голос
Оставьте свой голос
Анонимное голосование
Будет ли рост российского рынка к концу года?
-
Да
87% -
Нет
12%
Проголосовал 8 человек
Новостная лента
компании
Insider Summary
Insider Summary
| Reporting Name | Acquistion/Disposition | Owned | Transacted | Transaction Date |
|---|---|---|---|---|
| Janku Filip | A | 135000 | 135000 | 03 янв 2023 г. |
| Jones Jullian G | A | 77450 | 77450 | 03 янв 2023 г. |
| Tamboli Ajim | A | 129850 | 129850 | 03 янв 2023 г. |
| Townson Sharon | A | 78550 | 78550 | 03 янв 2023 г. |
| Castle John C. | A | 78500 | 78500 | 03 янв 2023 г. |
| Warmuth Markus | A | 472000 | 472000 | 03 янв 2023 г. |
| Nickson Philip | A | 123650 | 123650 | 03 янв 2023 г. |
| Wallace Owen B. | A | 135000 | 135000 | 03 янв 2023 г. |
| Janku Filip | A | 36000 | 36000 | 15 дек 2022 г. |
| Janku Filip | A | 36000 | 36000 | 31 окт 2022 г. |
Новостная лента
Monte Rosa Therapeutics to Present at Upcoming Investor Conferences
GlobeNewsWire
03 февр 2023 г. в 07:30
BOSTON, Feb. 03, 2023 (GLOBE NEWSWIRE) -- Monte Rosa Therapeutics, Inc. (NASDAQ: GLUE), a biotechnology company developing novel molecular glue degrader (MGD)-based medicines, today announced the company is scheduled to participate in fireside chats and industry panels, as well as present at the following upcoming investor events:
How Much Upside is Left in Monte Rosa Therapeutics (GLUE)? Wall Street Analysts Think 226.46%
Zacks Investment Research
25 янв 2023 г. в 11:18
The mean of analysts' price targets for Monte Rosa Therapeutics (GLUE) points to a 226.5% upside in the stock. While this highly sought-after metric has not proven reasonably effective, strong agreement among analysts in raising earnings estimates does indicate an upside in the stock.
Monte Rosa Therapeutics Announces Participation in Upcoming Investor Conferences
GlobeNewsWire
31 окт 2022 г. в 16:30
BOSTON, Oct. 31, 2022 (GLOBE NEWSWIRE) -- Monte Rosa Therapeutics, Inc. (NASDAQ: GLUE), a biotechnology company developing novel molecular glue degrader-based medicines, today announced the company will participate in the following upcoming investor conferences:
Monte Rosa Therapeutics to Present at 5th Annual Targeted Protein Degradation Summit and 34th EORTC-NCI-AACR Symposium
GlobeNewsWire
20 окт 2022 г. в 16:30
– New and Updated Preclinical Data Highlight Potential of GSPT1-directed Molecular Glue Degrader (MGD) MRT-2359 in the Treatment of MYC-driven Cancers –